There is a growing interest in adjuvant radiosurgery following resection of hematogenous brain metastases. We have identified 12 series reporting on a total of 480 patients treated to a tumor bed following microsurgery. These cases fall into 3 paradigms: adjuvant radiosurgery as an alternative to whole-brain radiotherapy (WBRT), radiosurgery as an intensification of adjuvant WBRT and adjuvant radiosurgery for patients having failed prior WBRT. For these paradigms the reported crude local control rates are 79%, 92% and 95%, respectively. The procedure appears well tolerate with approximately a 5% risk of late radiation necrosis. Prospective data is lagging behind clinical practice and plans for prospective trials are discussed.
Introduction
Hematogenous metastases have long been the most common adult brain tumor, representing between 100,000 to 200,000 cases per year in North America (1, 2) . Up to half of these patients will present with a single lesion. Local treatment of single metastases has been prospectively shown to improve survival in randomized trials. For most small lesions radiosurgery will provide local tumor control comparable to that of microsurgery (3) . However, in many cases, because of diagnostic ambiguity, mass effect or size, surgical resection will be necessary. Even though metastases do not tend to be highly invasive, local failures are common following these operations (4) . In addition, new metastases are common following surgery, occurring in approximately 50% of patients. Adjuvant whole-brain radiation (WBRT) reduces the incidence of both types of recurrences, decreases the risk of neurological death but does not appear to prolong overall survival (4, 5) .
In patients treated with stereotactic radiosurgery (SRS), where local control is acceptable without adjuvant treatment, deferring WBRT spares acute toxicity without impact on overall survival (despite more frequent brain recurrences). Although recurrences are known to impact on neurological function, a recent trial looking at detailed neurocognitive function post treatment showed a more frequent decline in Hopkins Verbal Learning Test (HVLT) scores at 4 months (23 % vs. 49 %, p not available) when WBRT was used upfront vs. deferred (6) . Tumor bed SRS has been proposed in a similar paradigm for surgical patients where it is expected to decrease the risk of local recurrence (where approximately half of failures occur) while sparing patients the toxicities of WBRT.
Although local recurrences are less frequent with the addition of whole-brain radiation radiotherapy (WBRT), on an actuarial basis local recurrences actually remain common. At 1-2 years, these occur in 20-72% of cases (4, (7) (8) (9) . In our own experience of 69 patients treated from 2000-2005, the 2-year actuarial rate of local recurrence after surgeon-reported gross total resection and WBRT was 67% (10) . We have thus chosen to apply tumor bed SRS in addition to WBRT in an attempt to maximize local control.
The third situation where tumor bed SRS has been used is the scenario where a patient has already been treated with WBRT prior to surgery and tumor bed SRS alone is as more appealing alternative than repeated WBRT or observation.
Although the treatment of metastatic lesions has long been the most common indication for SRS, tumor bed SRS is a relatively recent paradigm. If reported case series are used as an indication, there is a growing interest in these approaches of which we propose the first comprehensive review.
Materials and Methods
Cases series were identified through MEDLINE searches combining the terms "tumor bed", "microsurgery" or "postoperative" with "radiosurgery". The search (http:// www. pubmed.org) was performed up to January 2010. Publications in English and French were reviewed. References in manuscripts so identified were used to find additional reports, including those in the proceeding of national and international meetings.
Patient characteristics and outcomes were averaged across series with weighting for the number of cases in each.
For our own series, cases were identified in the McGill University Health Centre radiosurgery database. Cases were retained if patients had a single hematogenous metastasis treated with resection and adjuvant SRS boost in addition to WBRT. As immediate post-operative MRI imaging was infrequently performed, evaluation of the extent of resection was typically limited to the neurosurgeon's operative report.
A total of 38 patients, operated upon from December 2005 to October 2009, received a planned adjuvant combination of WBRT and SRS. WBRT schedules varied but 87% patients were treated with 30 Gy in 10 daily fractions. Based on scheduling concerns, SRS was delivered before, during or shortly after WBRT. The median interval between SRS and WBRT was 7 days.
Radiosurgery was delivered a median of 43 days after surgery using either fixed non-coplanar beams on a modified linear accelerator (BrainLAB, Heimstetten, Germany) or a dedicated robotic linear accelerator (Accuray, Sunnyvale, California). The surgical bed was typically defined with the help of pre-operative MRI images co-registered with the combination of thin-slice contrast-enhanced computed tomography and T1 weighted MRI studies acquired for SRS planning. The SRS dose was not adjusted for target size and was 10 Gy in all but 1 case. As this is a somewhat counterintuitive application of SRS for which the majority of the target volume is either cerebrospinal fluid or normal brain, an attempt was made to produce more homogeneous treatment plans -the median prescription isodose surface was 83%.
The planned follow-up schedule was for patients to have a contrast CT or MRI every 3 months. All local follow-up imaging was reviewed and reports were obtained from outside institutions. Cases were censured for local control and occurrence of new metastases at the time of last imaging. Outcomes were measured from the date of surgery. Survival, local control and occurrence of new metastases were calculated actuarially.
Results
Twelve series were identified reporting on a total of 480 patients (Table I) . Of these, 380 were included in 10 series where the aim was to reduce local recurrence whilst deferring WBRT, 38 patients, in a single series, were treated with tumor bed SRS in addition to WBRT and 79 were treated in a series of tumor bed SRS delivered in the context of post-WBRT surgical salvage.
Radiosurgery Without WBRT
Patients in these series were typically somewhat heterogeneous. Non-small cell lung cancer was the most common primary malignancy (42%). A third of patients had one or more additional synchronous brain metastases, in some cases also treated with surgery and tumor bed SRS. In the series of Jagannathan et al. (11) , 6% of patients did have WBRT in addition to SRS.
Treatment was delivered using a variety of radiosurgery technologies (60% Gamma Knife). The target volumes ranged from 0.1 to 66.8 cc but the mean/median of each series were rather homogeneous at 8.5 to 10.7 cc. Dosing was prescribed in a volume and location dependant fashion with mean/ median doses ranging from 15-19 Gy. In 2 of the series using linear accelerators, larger tumor cavities were treated in 2-5 sessions to higher total doses (22-30 Gy).
Local control is variably reported and actuarial local progression free survival is not available in 3 series. When weighted for the number of patients in each series, the overall crude local control is 79% and the estimated 1-year actuarial local control is 70%. Only in 2 series was it clear that the actuarial calculation censured patients at the time of the last imaging study. The crude averaged incidence of new metastases was 52%. The estimated median overall survival of the patients in the 10 series was 14.2 months.
Complications were variably reported-typically in terms of radiation necrosis, symptomatic T2 changes or treatmentrelated edema. Necrosis rates ranged from 0-6% and, when reported, other complications occurred in 11-27%.
Radiosurgery in Addition to WBRT
Other than our own experience, no additional manuscript was found describing the addition of SRS to post-operative WBRT. All our patients were treated with single fraction linac-based SRS. Thirty-eight patients had treatment to targets ranging from 2 to 61 cc (median 12 cc) with the dose prescribed at the 77-90% isodose surface (median 83%). These patients had been operated for metastases ranging in diameter from 13 to 60 mm (median 33). The most common primary malignancy was non-small cell lung cancer (63%), followed by breast (13%), melanoma (8%) and colo-rectal (8%).
In our series, follow-up imaging is available for all patients. 
Tumor Bed Radiosurgery After Prior WBRT
A single manuscript was identified reporting on the use of tumor bed SRS in patients having undergone salvage surgery after failure of WBRT. In this series from Wake Forest University Baptist Medical Center, patients treated after prior WBRT represented 79 of 143 cases of tumor bed SRS. These patients were treated from 2000 to 2005. All patients received a single fraction on a Gamma Knife unit. The median dose was 18 Gy (range 8-24 Gy) prescribed to a modal isodose surface of 50% (range 40-95%). The size of the target volumes was not reported.
The crude local recurrence rate was 5.1%. The median overall survival from SRS was 17 months. It is of note that, at the time of SRS, 42% of patients had no other site of metastatic disease.
Three patients (3.8%) required surgery for symptomatic radionecrosis following SRS. The mean prescription dose in Table 1 Reported series of tumor bed radiosurgery.
Institution
Year SRS is in keeping with published data and reflects the fact that, despite frequent intra-cranial failures, most patients with metastatic brain disease will die of extra-cranial progression.
In contrast to this approach, having dealt with frequent local recurrences despite WBRT, we have chosen to add SRS to WBRT. In addition to its documented efficacy in preventing new metastases, when combined with SRS, WBRT allows for greater dose-intensity at the tumor bed. For example, a 10 Gy SRS boost added to 30 Gy of fractionated radiotherapy is biologically more potent than a single 16 Gy dose of SRS. In addition, WBRT eliminates any risk of complete marginal miss from difficulties in defining a proper post-operative target. This is an issue highlighted in the experience of Soltys et al. that local recurrences occur less frequently when SRS plans are less conformal (20) . As the dose of SRS is reduced when added to WBRT, it opens this option of single fraction SRS to patients with large tumors and lesions approximating critical structures. These patients can be treated without compromising dose-intensity. As the therapy of extra-cranial disease improves, there may be renewed interest in an approach maximizing intra-cranial control.
There already is debate regarding the two main post-operative approaches tested in prospective trials: WBRT and observation. Despite two randomized trials (4, 5), each physician and patient can interpret the facts differently. The trials are underpowered to address the various subgroups of this heterogeneous patient population (such as patients with solitary metastases). In the absence of a documented difference in survival, we are ill equipped to objectively weigh the relative impacts of recurrence and treatment toxicity. Increased adoption of two new approaches will do little to simplify matters as they broaden the therapeutic spectrum. We may now be able to prevent fewer recurrences with less toxicity or prevent more recurrences with more toxicity.
In the patient having failed prior WBRT, the use of tumor bed SRS would appear less controversial. In this setting, the these patients was 17.3 Gy at the 50% isodose surface. The mean time to the occurrence of symptomatic radionecrosis requiring resection was 6.7 months.
Discussion
As evidenced by the growing number of publications over the past 5 years (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , there has been a growing trend for tumor bed radiosurgery. In most cases this has been as an alternative to adjuvant WBRT radiotherapy with isolated reports of its use as an intensification of WBRT or an adjuvant to post-WBRT salvage craniotomy.
The use as an alternative to WBRT is born in the background of growing evidence that the prevention of new metastases does not significantly impact on overall survival and may be associated with acute as well as late neuro-cognitive toxicity (6, 21) . As opposed to patients treated with primary SRS, local recurrences are a common problem when patients are observed following surgical resection. These recurrences are often more problematic than new small metastases more readily addressed with salvage SRS. If adjuvant tumor bed SRS provides local control equivalent to adjuvant WBRT, many physicians and patients would be comfortable deferring WBRT on the basis of current prospective data in the post-SRS setting (22) .
As the incidence of local recurrences will depend on patient selection, surgical skill and method of reporting, it is difficult to draw firm conclusions from retrospective data. With these caveats, the 21% crude tumor bed failure rate for the 363 reported cases of tumor bed SRS appears better than the expected 34-46% local failure rate in patients observed after surgical resection (4, 23, 24) . How much worse (if at all) this is to the local control afforded by WBRT is debatable. The 90% benchmark local control reported by Patchell et al. (4) has not been consistently reproduced in institutional series (8, 19) and the tumor bed SRS series are contaminated with patients known to have gross residual tumor. On the other hand, the 14.2 month median survival seen with tumor bed alternatives of Brachtherapy, local fractionated radiotherapy, repeat WBRT or observation are all lacking in both appeal and data.
In all three paradigms, the SRS appears well tolerated with risks similar to those of treating in situ brain metastases, i.e. approximately a 5% risk of late radiation necrosis.
As the number of patients treated keeps growing, it would seem proper to generate meaningful prospective data for these new treatment paradigms. Anything else than a single arm trial may not be realistic in the setting of WBRT failure but we feel that there is equipoise and interest in investigating the treatment of the radiation naïve patient. For this we have proposed two randomized trials in the post-operative setting. The first, a small scale randomized Phase II comparing SRS to WBRT+SRS, will start accruing in 2010. The second, a Phase III of WBRT vs. WBRT+SRS, is still in discussion at the cooperative group level.
Conclusions
The use of tumor bed SRS is reported with increasing frequency. The most common indication is as an alternative to WBRT. Its use is also reported as a local intensification to WBRT or a salvage measure in patients having required surgery after failure of prior WBRT. All three paradigms appear to have merit and we would hope that future prospective trials will help better quantify the pertinent therapeutic ratios.
